STOCK TITAN

Journey Medical Corp - DERM STOCK NEWS

Welcome to our dedicated news page for Journey Medical (Ticker: DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Journey Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Journey Medical's position in the market.

Rhea-AI Summary
Journey Medical (DERM) reports total revenues of $79.2 million for 2023, a 7% increase from 2022. Operating cost savings of $15.6 million exceeded guidance. New Drug Application for rosacea treatment candidate DFD-29 accepted by FDA with a PDUFA goal date of November 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.61%
Tags
earnings
-
Rhea-AI Summary
Journey Medical (DERM) reports total revenues of $79.2 million for 2023, a 7% increase from 2022. Operating cost savings of $15.6 million exceeded guidance. New Drug Application for rosacea treatment candidate DFD-29 accepted by FDA with a PDUFA goal date of November 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
earnings
-
Rhea-AI Summary
Journey Medical (DERM) announces FDA acceptance of NDA for DFD-29 for rosacea treatment with a PDUFA goal date of November 4, 2024. Positive Phase 3 trial data supports the efficacy and safety of DFD-29.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
clinical trial
Rhea-AI Summary
Journey Medical (DERM) announces FDA acceptance of NDA for DFD-29 for rosacea treatment with a PDUFA goal date of November 4, 2024. Positive Phase 3 trial data supports the efficacy and safety of DFD-29.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
clinical trial
-
Rhea-AI Summary
Journey Medical (DERM) to host conference call to discuss financial results and provide corporate update on March 21, 2024. The company focuses on selling FDA-approved prescription pharmaceutical products for dermatological conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
earnings
-
Rhea-AI Summary
Journey Medical (DERM) to host conference call to discuss financial results and provide corporate update on March 21, 2024. The company focuses on selling FDA-approved prescription pharmaceutical products for dermatological conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.18%
Tags
earnings
Rhea-AI Summary
Journey Medical Corporation (DERM) will participate in the 36th Annual ROTH Conference, with the President and CEO engaging in a fireside chat and one-on-one meetings. A webcast of the chat will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
conferences
-
Rhea-AI Summary
Journey Medical Corporation (DERM) will participate in the 36th Annual ROTH Conference, with the President and CEO engaging in a fireside chat and one-on-one meetings. A webcast of the chat will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
conferences
-
Rhea-AI Summary
Journey Medical Corporation (DERM) presents positive Phase 1 clinical trial results for DFD-29 at AAD Annual Meeting. The trial showed no significant safety issues and demonstrated the potential for DFD-29 to treat rosacea effectively. The New Drug Application for DFD-29 is under review by the U.S. FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
clinical trial
Rhea-AI Summary
Journey Medical Corporation (DERM) presents positive Phase 1 clinical trial results for DFD-29 at AAD Annual Meeting. The trial showed no significant safety issues and demonstrated the potential for DFD-29 to treat rosacea effectively. The New Drug Application for DFD-29 is under review by the U.S. FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
clinical trial
Journey Medical Corp

Nasdaq:DERM

DERM Rankings

DERM Stock Data

71.11M
7.65M
31.2%
10.19%
0.41%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Scottsdale